Harpoon Therapeutics to Present at the 63rd ASH Annual Meeting and Exposition
Abstract details:
- Title: An Interim Report on a Phase 1/2 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen for the Treatment of Relapsed/Refractory Multiple Myeloma
Publication Number: 1654
Submission ID: 148176
Authors:Sumit Madan , M.D., et al.
SessionName : 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster I
Poster Presentation Date and Time:Saturday, December 11, 2021 5:30 p.m. –7:30 p.m. ET
Location:Georgia World Congress Center , Hall B5
- Title: The Effects of BCMA Expression, Soluble BCMA, and Combination Therapeutics on the Anti-Tumor Activity of HPN217, a BCMA-Targeting Tri-Specific T Cell Engager Against Multiple Myeloma
Publication Number: 1185
Submission ID: 151880
Authors:Patrick Ng , Ph.D., et al.
SessionName : 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I
Poster Presentation Date and Time:Saturday, December 11, 2021 5:30 p.m. –7:30 p.m. ET
Location:Georgia World Congress Center , Hall B5
The posters will be available for viewing on
For more details about the ASH Annual Meeting please visit: https://www.hematology.org/meetings/annual-meeting.
About
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. For additional information about
Contacts:
Chief Financial Officer
650-443-7400
media@harpoontx.com
Westwicke ICR
Managing Director
858-356-5932
robert.uhl@westwicke.com

Source: Harpoon Therapeutics